Search Results - "BERGHORN, Elmer"

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial by Cella, David, Prof, Grünwald, Viktor, Prof, Nathan, Paul, MD, Doan, Justin, MPH, Dastani, Homa, PhD, Taylor, Fiona, MBiochem, Bennett, Bryan, PhD, DeRosa, Michael, PhD, Berry, Scott, PhD, Broglio, Kristine, PhD, Berghorn, Elmer, BSN, Motzer, Robert J, Prof

“…Summary Background In the phase 3 CheckMate 025 study, previously treated patients with advanced renal cell carcinoma who were randomly assigned to nivolumab…”
Get full text

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial by Weber, Jeffrey S, Prof, Gibney, Geoff, MD, Sullivan, Ryan J, MD, Sosman, Jeffrey A, Prof, Slingluff, Craig L, Prof, Lawrence, Donald P, MD, Logan, Theodore F, MD, Schuchter, Lynn M, Prof, Nair, Suresh, MD, Fecher, Leslie, MD, Buchbinder, Elizabeth I, MD, Berghorn, Elmer, BSN, Ruisi, Mary, MD, Kong, George, PhD, Jiang, Joel, PhD, Horak, Christine, PhD, Hodi, F Stephen, Dr

“…Summary Background Concurrent administration of the immune checkpoint inhibitors nivolumab and ipilimumab has shown greater efficacy than either agent alone in…”
Get full text

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study by Amin, Asim, Plimack, Elizabeth R, Ernstoff, Marc S, Lewis, Lionel D, Bauer, Todd M, McDermott, David F, Carducci, Michael, Kollmannsberger, Christian, Rini, Brian I, Heng, Daniel Y C, Knox, Jennifer, Voss, Martin H, Spratlin, Jennifer, Berghorn, Elmer, Yang, Lingfeng, Hammers, Hans J

“…Combination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor…”
Get full text

Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy by Hausheer, Frederick H., Schilsky, Richard L., Bain, Stacey, Berghorn, Elmer J., Lieberman, Frank

“…Peripheral neuropathy induced by cancer chemotherapy represents a large unmet need for patients due to the absence of treatment that can prevent or mitigate…”
Get full text

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study by Tomita, Yoshihiko, Fukasawa, Satoshi, Shinohara, Nobuo, Kitamura, Hiroshi, Oya, Mototsugu, Eto, Masatoshi, Tanabe, Kazunari, Kimura, Go, Yonese, Junji, Yao, Masahiro, Motzer, Robert J., Uemura, Hirotsugu, McHenry, M. Brent, Berghorn, Elmer, Ozono, Seiichiro

Get full text

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study by Amin, Asim, Plimack, Elizabeth R, Ernstoff, Marc S, Lewis, Lionel D, Bauer, Todd M, McDermott, David F, Carducci, Michael, Kollmannsberger, Christian, Rini, Brian I, Heng, Daniel Y C, Knox, Jennifer, Voss, Martin H, Spratlin, Jennifer, Berghorn, Elmer, Yang, Lingfeng, Hammers, Hans J

Get full text

Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study by DAUD, Adil, VALKOV, Nikola, HAUSHEER, Frederick, SULLIVAN, Daniel, CENTENO, Barbara, DERDERIAN, Jennifer, SULLIVAN, Patricia, MUNSTER, Pamela, URBAS, Patricia, DECONTI, Ronald C, BERGHORN, Elmer, ZHENMEI LIU

“…Purpose: A phase II trial of the novel camptothecin karenitecin (BNP1350) was conducted to determine its efficacy and tolerability in patients with metastatic…”
Get full text

Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma by Geoerger, Birgit, Bergeron, Christophe, Gore, Lia, Sender, Leonard, Dunkel, Ira J., Herzog, Cynthia, Brochez, Lieve, Cruz, Ofelia, Nysom, Karsten, Berghorn, Elmer, Simsek, Burcin, Shen, Jun, Pappo, Alberto

“…Ipilimumab is approved for the treatment of advanced melanoma in adults; however, little information on the efficacy and safety of ipilimumab in younger…”
Get full text

A phase 2 expansion study of ARV-766, a PROTACandrogen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC) by Petrylak, Daniel P., Stewart, Tyler F., Gao, Xin, Berghorn, Elmer, Lu, Haolan, Chan, Edward, Gedrich, Richard, Lang, Joshua Michael, McKean, Meredith

“…TPS290 Background: Patients with mCRPC inevitably develop resistance to available therapies and lack curative options. In patients treated with novel hormonal…”
Get full text

MP14-19 ARV-766, A PROTAC ANDROGEN RECEPTOR (AR) DEGRADER, COMBINED WITH ABIRATERONE IN NOVEL HORMONAL AGENT (NHA)-NA VE METASTATIC PROSTATE CANCER: PHASE 1 COHORT (PART C) OF A PHASE 1/2 STUDY by Shore, Neal, Lang, Joshua M., Geynisman, Daniel M., Stewart, Tyler F., Gao, Xin, Appleman, Leonard J., Dreicer, Robert, Dorff, Tanya, Berghorn, Elmer, Duperret, Elizabeth, Lu, Haolan, Chan, Edward, Garmezy, Benjamin, Petrylak, Daniel P.

Get full text

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study by Tomita, Yoshihiko, Fukasawa, Satoshi, Shinohara, Nobuo, Kitamura, Hiroshi, Oya, Mototsugu, Eto, Masatoshi, Tanabe, Kazunari, Kimura, Go, Yonese, Junji, Yao, Masahiro, Motzer, Robert J, Uemura, Hirotsugu, McHenry, M Brent, Berghorn, Elmer, Ozono, Seiichiro

“…Nivolumab improved overall survival (OS) and objective response rate (ORR) versus everolimus in previously treated patients with advanced renal cell carcinoma…”
Get full text

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC) by Gao, Xin, Burris III, Howard A., Vuky, Jacqueline, Dreicer, Robert, Sartor, A. Oliver, Sternberg, Cora N., Percent, Ivor John, Hussain, Maha H. A., Rezazadeh Kalebasty, Arash, Shen, John, Heath, Elisabeth I., Abesada-Terk, Guillermo, Gandhi, Sunil G., McKean, Meredith, Lu, Haolan, Berghorn, Elmer, Gedrich, Richard, Chirnomas, S. Debbie, Vogelzang, Nicholas J., Petrylak, Daniel P.

“…Abstract only 17 Background: ARV-110 is a first-in-class, oral PROteolysis TArgeting Chimera (PROTAC) protein degrader that selectively targets AR. Patients…”
Get full text

Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study by Cella, David, Gruenwald, Viktor, Nathan, Paul D., Doan, Justin, Dastani, Homa, Taylor, Fiona, Bennett, Bryan, DeRosa, Michael, Berry, Scott, Broglio, Kristine, Berghorn, Elmer, Motzer, Robert J.

“…Abstract only…”
Get full text

Quality of life in patients with advanced renal cell carcinoma treated with nivolumab versus everolimus in CheckMate 025, a randomised, phase 3 clinical trial by Cella, David, Grünwald, Viktor, Nathan, Paul, Doan, Justin, Dastani, Homa, Taylor, Fiona, Bennett, Bryan, DeRosa, Michael, Berry, Scott, Broglio, Kristine, Berghorn, Elmer, Motzer, Robert J

Get full text

Phase II study of ipilimumab (IPI) in children and adolescents with unresectable stage III or IV malignant melanoma (MEL) by Pappo, Alberto S., Bergeron, Christophe, Gore, Lia, Sender, Leonard S., Dunkel, Ira J., Herzog, Cynthia E., Brochez, Lieve, Cruz, Ofelia, Nysom, Karsten, Berghorn, Elmer, Simsek, Burcin, Shen, Jun, Geoerger, Birgit

“…Abstract only e21006 Background: IPI (anti-CTLA4) is approved for treatment of advanced MEL in adults, and more information on efficacy and safety of IPI in…”
Get full text

Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064) by Weber, Jeffrey S., Gibney, Geoffrey Thomas, Sullivan, Ryan J., Sosman, Jeffrey Alan, Slingluff, Craig L., Lawrence, Donald P., Logan, Theodore F., Schuchter, Lynn Mara, Nair, Suresh, Buchbinder, Elizabeth Iannotti, Berghorn, Elmer, Jiang, Joel, Horak, Christine E., Hodi, F. Stephen

“…Abstract only…”
Get full text

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine by Budman, D R, Meropol, N J, Reigner, B, Creaven, P J, Lichtman, S M, Berghorn, E, Behr, J, Gordon, R J, Osterwalder, B, Griffin, T

“…To evaluate the toxicology and pharmacology of an orally active fluoropyrimidine given as a continuous daily dose divided into two portions for 6 weeks, and to…”
Get more information

Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy: Toxicity of chemotherapy - The last decade by HAUSHEE, Frederick H, SCHILSKY, Richard L, BARN, Stacey, BERGHORN, Elmer J, LIEBERMAN, Frank

Get full text

Final results of a phase I and pharmacokinetic study of ?-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors by Johansen, Mary, Zukowski, Thomas, Hoff, Paulo M., Newman, Robert A., Ni, Dan, Hutto, Toni, Abbruzzeese, James, Berghorn, Elmer, Hausheer, Frederick, Madden, Timothy

Get full text

Final results of a phase I and pharmacokinetic study of γ-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors by JOHANSEN, Mary, ZUKOWSKI, Thomas, HOFF, Paulo M, NEWMAN, Robert A, DAN NI, HUTTO, Toni, ABBRUZZEESE, James, BERGHORN, Elmer, HAUSHEER, Frederick, MADDEN, Timothy

“…To determine the maximum tolerated dose (MTD) of gamma-methylene-10-deazaaminopterin (MDAM), a unique antifolate structurally similar to methotrexate (MTX), in…”
Get full text